- Home
- ANL vs CBUS Comparison
ANL vs CBUS Comparison
Compare ANL & CBUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANL
- CBUS
- Stock Information
- Founded
- ANL 2004
- CBUS 2010
- Country
- ANL Cayman Islands
- CBUS United States
- Employees
- ANL N/A
- CBUS N/A
- Industry
- ANL
- CBUS Agricultural Chemicals
- Sector
- ANL
- CBUS Industrials
- Exchange
- ANL Nasdaq
- CBUS Nasdaq
- Market Cap
- ANL 61.8M
- CBUS 72.0M
- IPO Year
- ANL 2023
- CBUS 2017
- Fundamental
- Price
- ANL $1.79
- CBUS $1.39
- Analyst Decision
- ANL Hold
- CBUS Strong Buy
- Analyst Count
- ANL 1
- CBUS 3
- Target Price
- ANL N/A
- CBUS $22.00
- AVG Volume (30 Days)
- ANL 9.3K
- CBUS 216.8K
- Earning Date
- ANL 09-26-2025
- CBUS 11-06-2025
- Dividend Yield
- ANL N/A
- CBUS N/A
- EPS Growth
- ANL N/A
- CBUS N/A
- EPS
- ANL N/A
- CBUS N/A
- Revenue
- ANL N/A
- CBUS $4,846,000.00
- Revenue This Year
- ANL N/A
- CBUS $17.67
- Revenue Next Year
- ANL N/A
- CBUS $63.43
- P/E Ratio
- ANL N/A
- CBUS N/A
- Revenue Growth
- ANL N/A
- CBUS 63.66
- 52 Week Low
- ANL $1.10
- CBUS $1.20
- 52 Week High
- ANL $3.89
- CBUS $6.10
- Technical
- Relative Strength Index (RSI)
- ANL 60.57
- CBUS 51.59
- Support Level
- ANL $1.65
- CBUS N/A
- Resistance Level
- ANL $1.88
- CBUS $1.53
- Average True Range (ATR)
- ANL 0.10
- CBUS 0.07
- MACD
- ANL 0.00
- CBUS -0.03
- Stochastic Oscillator
- ANL 58.02
- CBUS 91.15
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
About CBUS Cibus Inc.
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.